Skip to content

Somatically acquired immunodeficiency

Somatically acquired immunodeficiency

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00037374
Enrollment
20000
Registered
2025-07-10
Start date
2026-11-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe infections or suspected immunodeficiency: A00–B99 G00–G09 J00–J22 L00–L08 N10–N12, N30 T81.4 Z22

Interventions

Group 1: The study includes patients with unusually severe infections or a clinical suspicion of congenital or somatic immunodeficiency. All patient recruitment and sample collection will take place e

Sponsors

Centre d'Etudes des Déficits Immunitaires (CEDI), Hôpital Necker - Enfants Malades
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with rare genetic disorders affecting the ribosome and the translation machinery

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
The aim of the study is to systematically characterize the immunological, clinical, and developmentally dependent features of a rare, severe monogenic disease across the lifespan, in order to better understand its pathophysiology and identify targets for future therapies.

Secondary

MeasureTime frame
Reaching of a mechanistic understanding of the disease origin and development.

Countries

France

Contacts

Public ContactJonathan Bohlen

Genzentrum der LMU

bohlen@genzentrum.lmu.de+49 89 2180 71055

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026